Peer-reviewed veterinary case report
Anti-nerve growth factor antibodies to control pain in dogs and cats
By Enomoto, Masataka et al.·Published in The Veterinary record·2019·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats.
Plain-English summary
A new treatment using anti-nerve growth factor (NGF) monoclonal antibodies is being tested for managing pain in dogs and cats with osteoarthritis. This therapy targets a specific pathway involved in pain signaling and has shown promise in early clinical trials. Although not yet approved for use in humans, the results so far suggest that it could effectively reduce chronic pain in pets suffering from arthritis. As research continues, this could become a valuable option for pet owners looking for relief for their furry friends.
People also search for: dog osteoarthritis pain treatment · cat arthritis pain relief · anti-NGF therapy for pets
Abstract
Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30368458/